Lancet Infectious Diseases Publishes Independent Double-Blind Study Validating MeMed#s Immunoxpert(TM) Blood Test#s Ability to Accurately Distinguish Between Bacterial and Viral Infections in Children

Food and Healthcare Press Releases Thursday December 22, 2016 17:50
TIRAT CARMEL, Israel--22 Dec--PRNewswire/InfoQuest
Use of ImmunoXpert has the potential to improve patient management and reduce drug resistance due to antibiotic overuse
ImmunoXpert significantly outperformed routine tests

MeMed Ltd. announced today Lancet Infectious Diseases' publication of the results from OPPORTUNITY , an international multicenter, external double-blinded clinical study in children led by researchers from the University Medical Center, Utrecht. OPPORTUNITY met its primary endpoint, independently confirming that MeMed's novel blood test, ImmunoXpert accurately distinguishes between bacterial and viral infections in children. ImmunoXpert was also shown to significantly outperform routine tests.

(Logo: )

"The results are beyond our expectations," said Professor Louis J. Bont, MD, PhD, Division of Pediatric Immunology and Infectious Disease, University Medical Center, Utrecht, the Netherlands and Principal Investigator. "We independently confirmed that the test is highly accurate in children, with significantly better diagnosis compared to any of the routine tests we use today. It has the potential to significantly aid us in reducing antibiotic overuse and combating bacterial resistance. To our knowledge, this is the first prospective validation study for a diagnostic assay differentiating between bacterial and viral infections that was double-blinded."

"MeMed took the unusual risk of allowing leading experts to independently evaluate its tests in a double-blind manner. We are excited that the new results corroborate the findings of our previous   CURIOSITY study," said Eran Eden, PhD, MeMed CEO. "This is another important milestone in our continuous efforts to generate clinical evidence of the highest quality to support our tests."

"Unlike most traditional diagnostics, which focus on identifying the disease-causing virus or bacteria, ImmunoXpert looks at the immune system where it identifies markers that indicate if the patient is fighting a bacterial or viral infection," said Kfir Oved, MD, PhD, MeMed Chief Technology Officer.   "This immune system-based approach overcomes the inherent limitations of many traditional diagnostic tools. It is accurate and rapid and can diagnose infections that are not readily accessible, such as pneumonia."

The study evaluated 577 children aged 2 - 60 months with lower respiratory tract infections or fever without a source. ImmunoXpert was highly accurate in distinguishing between clear bacterial and viral infections with a sensitivity of 88%, specificity of 93% and a negative predictive value of 98%. ImmunoXpert outperformed routine tests, reducing the number of cases in which viral infections were erroneously diagnosed as bacterial, by more than 50%. These findings highlight the significant potential of ImmunoXpert to aid in the reduction of unnecessary antibiotic prescriptions.

Bacterial and viral infections are often clinically indistinguishable, leading to antibiotic overuse and contributing to the spread of antibiotic resistance, which according to the World Health Organization, is approaching crisis proportions.[1] Paradoxically, the inability to rapidly differentiate infections also results in the underuse of antibiotics, estimated to occur in 20-40% of all bacterial infections, putting patients at risk of complications and increasing healthcare costs.[2] A test that can accurately and quickly distinguish between bacterial and viral infections has the potential to improve patient management by providing physicians with information to aid and support care decisions and reduce both the overuse and underuse of antibiotics.

MeMed continues to collaborate with clinical thought leaders on a series of large, multi-center clinical studies, enrolling over 10,000 patients, and has plans underway to conduct clinical studies in the U.S. in 2017. The company is partnering with international stakeholders from industry and government to facilitate global availability of its tests.

About MeMed MeMed is dedicated to improving patient lives through research, development and commercialization of pioneering tests that monitor the body's immune state. Its tests decode the immune system's distinct responses to different health and disease states. The company focuses on providing rapid, accurate and actionable diagnostic solutions for acute infectious diseases and inflammatory disorders in the hospital and community. Its first test, ImmunoXpert, has demonstrated the ability to accurately detect whether a patient has a bacterial or viral infection, with the aim of empowering physicians to make better informed antibiotic treatment decisions. ImmunoXpert is cleared for clinical use in the European Union, Switzerland and Israel. It is currently in pilot distribution in these territories with a broader commercial roll-out underway. MeMed's second-generation test for rapid (within minutes) point-of-care testing is under development. For additional information, please visit .

1.   WHO | WHO Director-General briefs UN on antimicrobial resistance at
2. Craig, J.C. et al. BMJ 340, c1594 (2010).
Media Contact:
Betsy Stevenson
(M) +1-860-984-1424
Business Development Contact:
Asi Cohen-Dotan, PhD
Phone: +972-4-8500302
Source: MeMed Ltd

Latest Press Release

Walgreens Boots Alliance and Microsoft establish strategic partnership to transform health care delivery

- Companies aim to improve health outcomes and lower overall costs with enhanced digital and retail experiences and an R&D commitment to build health care solutions through seven-year agreement Walgreens Boots Alliance Inc. (WBA) and Microsoft Corp....

Ascensia Diabetes Care Announces Global Partnership With POCTech to Distribute and Co-develop Continuous Glucose Monitoring Systems

Ascensia Diabetes Care today announced it has entered into a global alliance with Zhejiang POCTech, Co., Ltd (POCTech), a developer and manufacturer of continuous glucose monitoring (CGM) systems. (Logo:...

MGI Announces Milestone of 1,000 Sequencers Installed and Opens Early Access Program for Groundbreaking Ultra-High-Throughput Sequencer, MGISEQ-T7

MGI, established in 2016 as a subsidiary of global genomics leader BGI Group, announced it has reached a new milestone of 1,000 MGI sequencers installed in 16 countries. MGI Chief Operating Officer Dr. Hui Jiang also announced the availability of MGI's...

Gift of Life Donor Program is U.S. Leader in Saving Lives

For the 11th consecutive year, Gift of Life Donor Program is the nation's leading organ procurement organization (OPO), coordinating the most life-saving organs for transplant among all 58 U.S. OPOs. Gift of Life broke two national records in 2018,...

Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat

Licensing rights are worldwide excluding US, Canada, Japan and South AmericaHelsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Menarini, an Italian biopharmaceutical Group active in 136 countries worldwide, today...

Related Topics